Ae1 Ae3 Antibody Bafilomycin A1 Bile Acid Assay Bioassay Blog Ch 223191 Choline Acetyltransferase Antibody Ldn 193189 Medium Mip 1B peptide Polyclonal Purification Ru 58841 Trypsin Activity Assay Tubastatin A Uric Acid Assay Valproic Acid Sodium Salt Western Blot
Reconstitution of the destruction complex defines roles of AXIN polymers and APC in β-catenin capture, phosphorylation, and ubiquitylation
The Wnt/β-catenin pathway is a extremely conserved, incessantly mutated developmental and most cancers pathway. Its output is outlined primarily by β-catenin’s phosphorylation- and ubiquitylation-dependent proteasomal degradation, initiated by the multi-protein β-catenin destruction advanced.
The exact mechanisms underlying destruction advanced perform have remained unknown, largely due to the shortage of appropriate in vitro techniques. Right here we describe the in vitro reconstitution of an energetic human β-catenin destruction advanced from purified parts, recapitulating advanced meeting, β-catenin modification, and degradation.
We reveal that AXIN1 polymerization and APC promote β-catenin seize, phosphorylation, and ubiquitylation. APC facilitates β-catenin’s flux by the advanced by limiting ubiquitylation processivity and straight interacts with the SCFβ-TrCP E3 ligase advanced in a β-TrCP-dependent method.
Oncogenic APC truncation variants, though a part of the advanced, are functionally impaired. Nonetheless, even essentially the most severely truncated APC variant promotes β-catenin recruitment. These findings exemplify the ability of biochemical reconstitution to interrogate the molecular mechanisms of Wnt/β-catenin signaling.
A Community Pharmacology Strategy to Examine the Mechanism of Erjing Prescription in Sort 2 Diabetes
Erjing prescription (EJP) was an historical system that was recorded within the Normal Medical Assortment of Royal Benevolence of the Track Dynasty. It has been incessantly used to deal with sort 2 diabetes mellitus (T2DM) within the lengthy historical past of China.
The system consists of Lycium barbarum L. and Polygonatum sibiricum F. Delaroche with a ratio of 1 : 1. This examine aimed to establish the potential results and mechanisms of EJP remedy T2DM. The goal proteins and potential pathways of EJP in T2DM remedy have been investigated by the strategy of community pharmacology and real-time PCR (RT-PCR).
99 diabetes-related proteins have been regulated by 56 bioactive constituents in EJP in 26 sign pathways by Cytoscape dedication. In accordance with GO evaluation, 606 genes entries have been enriched. The PPI community prompt that AKT1, EGF, EGFR, MAPK1, and GSK3β proteins have been core genes. Among the many 26 sign pathways, the PI3K-AKT sign pathway was examined by the RT-PCR.
The expression stage of PI3K p85, AKT1, GSK3β, and Myc mRNA of this pathway was regulated by EJP. The examine based mostly on community pharmacology and RT-PCR evaluation revealed that the blood sugar stage was regulated by EJP by way of regulating the PI3K-AKT sign pathway. Loads of new remedy strategies for T2DM utilizing EJP have been supplied by community pharmacology evaluation.
Proteomics and Phosphoproteomics Profiling of Drug-Addicted BRAFi-Resistant Melanoma Cells
Acquired resistance to MAPK inhibitors limits the medical efficacy in melanoma remedy. We and others have lately proven that BRAF inhibitor (BRAFi)-resistant melanoma cells can develop a dependency on the therapeutic medication to which they’ve acquired resistance, making a vulnerability for these cells that may probably be exploited in most cancers remedy.
In drug-addicted melanoma cells, it was proven that this induction of cell loss of life was preceded by a particular ERK2-dependent phenotype change; nevertheless, the underlying molecular mechanisms are largely missing.
To extend the molecular understanding of this drug dependency, we utilized a mass spectrometry-based proteomic strategy on BRAFi-resistant BRAFMUT 451Lu cells, during which ERK1, ERK2, and JUNB have been silenced individually utilizing CRISPR-Cas9.
Inactivation of ERK2 and, to a lesser extent, JUNB prevents drug dependancy in these melanoma cells, whereas, conversely, knockout of ERK1 fails to reverse this phenotype, exhibiting a response much like that of management cells.
Our evaluation reveals that ERK2 and JUNB share comparable proteome responses dominated by reactivation of cell division. Importantly, we discover that EMT activation in drug-addicted melanoma cells upon drug withdrawal is affected by silencing ERK2 however not ERK1.
Furthermore, transcription issue (regulator) enrichment reveals that PIR acts as an effector of ERK2 and phosphoproteome evaluation reveals that silencing of ERK2 however not ERK1 results in amplification of GSK3 kinase exercise. Our outcomes depict potential mechanisms of drug dependancy in melanoma, which can present a information for therapeutic methods in drug-resistant melanoma.
Inhibition of AKT Signaling Alters βIV Spectrin Distribution on the AIS and Will increase Neuronal Excitability
The axon preliminary section (AIS) is a extremely regulated subcellular area required for neuronal firing. Adjustments within the AIS protein composition and distribution are a type of structural plasticity, which powerfully regulates neuronal exercise and will underlie a number of neuropsychiatric and neurodegenerative problems.
Regardless of its physiological and pathophysiological relevance, the signaling pathways mediating AIS protein distribution are nonetheless poorly studied. Right here, we used confocal imaging and whole-cell patch clamp electrophysiology in main hippocampal neurons to check how AIS protein composition and neuronal firing diversified in response to chose kinase inhibitors focusing on the AKT/GSK3 pathway, which has beforehand been proven to phosphorylate AIS proteins.
Picture-based options representing the mobile sample distribution of the voltage-gated Na+ (Nav) channel, ankyrin G, βIV spectrin, and the cell-adhesion molecule neurofascin have been analyzed, revealing βIV spectrin as essentially the most delicate AIS protein to AKT/GSK3 pathway inhibition.
Inside this pathway, inhibition of AKT by triciribine has the best impact on βIV spectrin localization to the AIS and its subcellular distribution inside neurons, a phenotype that Assist Vector Machine classification was in a position to precisely distinguish from management.
Therapy with triciribine additionally resulted in elevated excitability in main hippocampal neurons. Thus, perturbations to signaling mechanisms throughout the AKT pathway contribute to adjustments in βIV spectrin distribution and neuronal firing that could be related to neuropsychiatric and neurodegenerative problems.
Copper publicity induces hepatic G0/G1 cell-cycle arrest by suppressing the Ras/PI3K/Akt signaling pathway in mice
Copper (Cu), as a typical chemical contaminant in surroundings, is understood to be poisonous at excessive concentrations. The present analysis demonstrates the results of copper upon hepatocyte cell-cycle development (CCP) in mice. Institute of most cancers analysis (ICR) mice (n = 240) at an age of 4 weeks have been divided randomly into teams handled with totally different doses of Cu (0, 4, 8, and 16 mg/kg) for 21 and 42 days.
Anti-GSK3B antibody |
|||
| STJ113773 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-GSK3B antibody |
|||
| STJ113841 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-GSK3B antibody |
|||
| STJ119229 | St John's Laboratory | 100 µl | EUR 332.4 |
Anti-GSK3B Antibody |
|||
| STJ501295 | St John's Laboratory | 100 µg | EUR 571.2 |
Anti-GSK3B antibody |
|||
| STJ27912 | St John's Laboratory | 100 µl | EUR 495.6 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-GSK3B antibody |
|||
| STJ23879 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-GSK3B antibody |
|||
| STJ23880 | St John's Laboratory | 100 µl | EUR 332.4 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Rabbit Polyclonal antibody Anti-CRBN |
|||
| Anti-CRBN | ImmunoStep | 50 µg | EUR 418.8 |
Anti-GSK3B Antibody (Biotin) |
|||
| STJ501296 | St John's Laboratory | 100 µg | EUR 703.2 |
Anti-GSK3B Antibody (FITC) |
|||
| STJ501297 | St John's Laboratory | 100 µg | EUR 703.2 |
anti-GSK3B (3D10) |
|||
| LF-MA30340 | Abfrontier | 100 ul | EUR 583.2 |
|
Description: Mouse Monoclonal to GSK3B |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Hu-48T | DL Develop | 48T | EUR 620.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Hu-96T | DL Develop | 96T | EUR 807.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Human Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Mu-48T | DL Develop | 48T | EUR 632.4 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Mu-96T | DL Develop | 96T | EUR 825.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Ra-48T | DL Develop | 48T | EUR 658.8 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| DLR-GSK3b-Ra-96T | DL Develop | 96T | EUR 861.6 |
|
Description: A sandwich quantitative ELISA assay kit for detection of Rat Glycogen Synthase Kinase 3 Beta (GSK3b) in samples from tissue homogenates, cell lysates or other biological fluids. |
|||
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 652.8 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 907.2 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 668.4 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 928.8 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 699.6 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RDR-GSK3b-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 973.2 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Hu-48Tests | Reddot Biotech | 48 Tests | EUR 625.2 |
Human Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Hu-96Tests | Reddot Biotech | 96 Tests | EUR 867.6 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Mu-48Tests | Reddot Biotech | 48 Tests | EUR 639.6 |
Mouse Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Mu-96Tests | Reddot Biotech | 96 Tests | EUR 888 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Ra-48Tests | Reddot Biotech | 48 Tests | EUR 668.4 |
Rat Glycogen Synthase Kinase 3 Beta (GSK3b) ELISA Kit |
|||
| RD-GSK3b-Ra-96Tests | Reddot Biotech | 96 Tests | EUR 930 |
Anti-GSK3b (Ab-9) Antibody |
|||
| A00791-1 | BosterBio | 100ul | EUR 476.4 |
|
Description: Rabbit Polyclonal GSK3b (Ab-9) Antibody. Validated in IF, IHC, WB and tested in Human, Mouse, Rat. |
|||
Anti-Phospho-GSK3B-(Y216) antibody |
|||
| STJ116370 | St John's Laboratory | 100 µl | EUR 471.6 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Phospho-GSK3B-(Y216) antibody |
|||
| STJ110852 | St John's Laboratory | 100 µl | EUR 471.6 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
Anti-Phospho-GSK3B-(S9) antibody |
|||
| STJ22160 | St John's Laboratory | 100 µl | EUR 471.6 |
|
Description: The protein encoded by this gene is a serine-threonine kinase, belonging to the glycogen synthase kinase subfamily. It is involved in energy metabolism, neuronal cell development, and body pattern formation. Polymorphisms in this gene have been implicated in modifying risk of Parkinson disease, and studies in mice show that overexpression of this gene may be relevant to the pathogenesis of Alzheimer disease. Alternatively spliced transcript variants encoding different isoforms have been found for this gene. |
|||
GSK3b antibody |
|||
| 70R-11869 | Fitzgerald | 100 ug | EUR 501.6 |
|
Description: Rabbit polyclonal GSK3b antibody |
|||
GSK3B antibody |
|||
| 70R-17615 | Fitzgerald | 50 ul | EUR 522 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3B antibody |
|||
| 70R-15005 | Fitzgerald | 100 ul | EUR 470.4 |
|
Description: Rabbit polyclonal GSK3B antibody |
|||
GSK3B antibody |
|||
| 38353-100ul | SAB | 100ul | EUR 302.4 |
GSK3B antibody |
|||
| 38616-100ul | SAB | 100ul | EUR 302.4 |
GSK3B Antibody |
|||
| 36918-100ul | SAB | 100ul | EUR 302.4 |
GSK3B antibody |
|||
| 10R-1862 | Fitzgerald | 100 ul | EUR 483.6 |
|
Description: Mouse monoclonal GSK3B antibody |
|||
GSK3B Antibody |
|||
| ABD6806 | Lifescience Market | 100 ug | EUR 525.6 |
GSK3B Antibody |
|||
| ABD7231 | Lifescience Market | 100 ug | EUR 525.6 |
GSK3B Antibody |
|||
| BF0695 | Affbiotech | 200ul | EUR 540 |
GSK3B Antibody |
|||
| 1-CSB-PA080166 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC;WB:1:1000-2000.IHC:1:200-500 |
|||
GSK3B Antibody |
|||
| CSB-PA939628- | Cusabio | EUR 402 | |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| CSB-PA939628-100ul | Cusabio | 100ul | EUR 379.2 |
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: ELISA, WB;WB:1:500-1:3000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA002848 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, IP, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.IP:2-5ug/mglysate.ELISA:1/20000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009038 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/5000 |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963GA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse, Rat, Pig. This antibody is Unconjugated. Tested in the following application: ELISA, WB |
|||
GSK3B Antibody |
|||
| 1-CSB-PA009963LA01HU | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3B. Recognizes GSK3B from Human, Mouse. This antibody is Unconjugated. Tested in the following application: ELISA, WB, IF; Recommended dilution: WB:1:2000-1:10000, IF:1:50-1:500 |
|||
GSK3B Antibody |
|||
| F51046-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
GSK3B Antibody |
|||
| F51046-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Gsk3b Antibody |
|||
| F44221-0.08ML | NSJ Bioreagents | 0.08 ml | EUR 165 |
Gsk3b Antibody |
|||
| F44221-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Phospho-GSK3b antibody |
|||
| 70R-11870 | Fitzgerald | 100 ug | EUR 630 |
|
Description: Rabbit polyclonal Phospho-GSK3b antibody |
|||
GSK3B (pY216) Antibody |
|||
| 20-abx000312 | Abbexa |
|
|
GSK3B (pY216) Antibody |
|||
| 20-abx123289 | Abbexa |
|
|
GSK3A / GSK3B Antibody |
|||
| 20-abx328487 | Abbexa |
|
|
GSK3B Conjugated Antibody |
|||
| C36918 | SAB | 100ul | EUR 476.4 |
GSK3B Conjugated Antibody |
|||
| C38353 | SAB | 100ul | EUR 476.4 |
GSK3A/GSK3B Antibody |
|||
| 1-CSB-PA002838 | Cusabio |
|
|
|
Description: A polyclonal antibody against GSK3A/GSK3B. Recognizes GSK3A/GSK3B from Human, Mouse, Rat. This antibody is Unconjugated. Tested in the following application: WB, IHC, ELISA;WB:1/500-1/2000.IHC:1/100-1/300.ELISA:1/20000 |
|||
GSK3B Polyclonal Antibody |
|||
| A62706-020 | EpiGentek | 20 ul | EUR 117.7 |
GSK3B Polyclonal Antibody |
|||
| A62706-050 | EpiGentek | 50 ul | EUR 302.5 |
GSK3B Polyclonal Antibody |
|||
| A62706-100 | EpiGentek | 100 ul | EUR 423.5 |
GSK3B Polyclonal Antibody |
|||
| A62706 | EpiGentek |
|
|
GSK3B Polyclonal Antibody |
|||
| A72446 | EpiGentek |
|
|
GSK3B Polyclonal Antibody |
|||
| A72447 | EpiGentek |
|
|
GSK3B Polyclonal Antibody |
|||
| A72448 | EpiGentek |
|
|
GSK3B Polyclonal Antibody |
|||
| A72450 | EpiGentek |
|
|
GSK3B Polyclonal Antibody |
|||
| A72446-050 | EpiGentek | 50 ul | EUR 302.5 |
GSK3B Polyclonal Antibody |
|||
| A72446-100 | EpiGentek | 100 ul | EUR 423.5 |
GSK3B Polyclonal Antibody |
|||
| A72447-050 | EpiGentek | 50 ul | EUR 302.5 |
GSK3B Polyclonal Antibody |
|||
| A72447-100 | EpiGentek | 100 ul | EUR 423.5 |
GSK3B Polyclonal Antibody |
|||
| A72448-050 | EpiGentek | 50 ul | EUR 302.5 |
GSK3B Polyclonal Antibody |
|||
| A72448-100 | EpiGentek | 100 ul | EUR 423.5 |
GSK3B Polyclonal Antibody |
|||
| A72450-050 | EpiGentek | 50 ul | EUR 377.3 |
GSK3B Polyclonal Antibody |
|||
| A72450-100 | EpiGentek | 100 ul | EUR 577.5 |
Sheep Anti Fitc Polyclonal Antibody,Alk. Phos. |
|||
| DPBT-68234SF | Creative Diagnostics | 1 ml | EUR 889.2 |
BSA antibody (Alk Phos) |
|||
| 60R-AS001alk | Fitzgerald | 1 ml | EUR 314.4 |
|
Description: Sheep polyclonal BSA antibody (Alk Phos) conjugated |
|||
Biotin antibody (Alk Phos) |
|||
| 60R-1001 | Fitzgerald | 1 mg | EUR 297.6 |
|
Description: Biotin antibody (Alk Phos) |
|||
Phos-SOX2 Antibody (pS249) |
|||
| F48637-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Phos-ERBB2 Antibody (pY1127) |
|||
| F48692-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 389 |
Phos-PTEN Antibody (pS229) |
|||
| F48735-0.4ML | NSJ Bioreagents | 0.4 ml | EUR 379 |
Polyclonal Goat anti-GST α-form |
|||
| GST-ANTI-1 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST μ-form |
|||
| GST-ANTI-2 | Detroit R&D | 50 uL | EUR 336 |
Polyclonal Goat anti-GST p-form |
|||
| GST-ANTI-3 | Detroit R&D | 50 uL | EUR 336 |
Rabbit anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0121 | Fitzgerald | 1 mg | EUR 478.8 |
|
Description: Rabbit anti Bovine IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0135 | Fitzgerald | 1 mg | EUR 450 |
|
Description: Rabbit anti Bovine IgG secondary antibody (Alk Phos) |
|||
Goat anti Bovine IgG (Alk Phos) |
|||
| 43C-CB0142 | Fitzgerald | 1 mg | EUR 442.8 |
|
Description: Goat anti Bovine IgG secondary antibody (Alk Phos) |
|||
Goat anti Cat IgG (Alk Phos) |
|||
| 43C-CB0221 | Fitzgerald | 1 mg | EUR 475.2 |
|
Description: Goat anti Cat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Cat IgG (Alk Phos) |
|||
| 43C-CB0228 | Fitzgerald | 1 mg | EUR 458.4 |
|
Description: Rabbit anti Cat IgG secondary antibody (Alk Phos) |
|||
Goat anti Cat IgG (Alk Phos) |
|||
| 43C-CB0235 | Fitzgerald | 1 mg | EUR 453.6 |
|
Description: Goat anti Cat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Chicken IgG (Alk Phos) |
|||
| 43C-CB0321 | Fitzgerald | 1 mg | EUR 478.8 |
|
Description: Rabbit anti Chicken IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Chicken IgG (Alk Phos) |
|||
| 43C-CB0328 | Fitzgerald | 1 mg | EUR 474 |
|
Description: Rabbit anti Chicken IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Dog IgG (Alk Phos) |
|||
| 43C-CB0414 | Fitzgerald | 1 mg | EUR 478.8 |
|
Description: Rabbit anti Dog IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Dog IgG (Alk Phos) |
|||
| 43C-CB0421 | Fitzgerald | 1 mg | EUR 458.4 |
|
Description: Rabbit anti Dog IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0528 | Fitzgerald | 1 mg | EUR 458.4 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0535 | Fitzgerald | 1 mg | EUR 450 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Goat IgG (Alk Phos) |
|||
| 43C-CB0542 | Fitzgerald | 500 µg | EUR 470.4 |
|
Description: Rabbit anti Goat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0949 | Fitzgerald | 1 mg | EUR 526.8 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0956 | Fitzgerald | 1 mg | EUR 450 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgG (Alk Phos) |
|||
| 43C-CB0963 | Fitzgerald | 1 mg | EUR 433.2 |
|
Description: Goat anti Human IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Human IgG (Alk Phos) |
|||
| 43C-CB0970 | Fitzgerald | 1 mg | EUR 450 |
|
Description: Rabbit anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgG (Alk Phos) |
|||
| 43C-CB0978 | Fitzgerald | 1 mg | EUR 483.6 |
|
Description: Goat anti Human IgG secondary antibody (Alk Phos) |
|||
Goat anti Human IgM (Alk Phos) |
|||
| 43C-CB0999 | Fitzgerald | 1 mg | EUR 456 |
|
Description: Goat anti Human IgM secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1142 | Fitzgerald | 1 mg | EUR 466.8 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1149 | Fitzgerald | 1 mg | EUR 577.2 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1156 | Fitzgerald | 1 mg | EUR 433.2 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Goat anti Rabbit IgG (Alk Phos) |
|||
| 43C-CB1163 | Fitzgerald | 1 mg | EUR 542.4 |
|
Description: Goat anti Rabbit IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgG (Alk Phos) |
|||
| 43C-CB1249 | Fitzgerald | 1 mg | EUR 486 |
|
Description: Rabbit anti Rat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgG (Alk Phos) |
|||
| 43C-CB1256 | Fitzgerald | 1 mg | EUR 478.8 |
|
Description: Rabbit anti Rat IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Rat IgM (Alk Phos) |
|||
| 43C-CB1270 | Fitzgerald | 1 mg | EUR 549.6 |
|
Description: Rabbit anti Rat IgM secondary antibody (Alk Phos) |
|||
Goat anti Rat IgM (Alk Phos) |
|||
| 43C-CB1277 | Fitzgerald | 1 mg | EUR 560.4 |
|
Description: Goat anti Rat IgM secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1328 | Fitzgerald | 1 mg | EUR 486 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1335 | Fitzgerald | 500 µg | EUR 564 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1342 | Fitzgerald | 1 mg | EUR 475.2 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Rabbit anti Sheep IgG (Alk Phos) |
|||
| 43C-CB1349 | Fitzgerald | 500 µg | EUR 562.8 |
|
Description: Rabbit anti Sheep IgG secondary antibody (Alk Phos) |
|||
Goat anti Monkey IgG (Alk Phos) |
|||
| 43C-CB1611 | Fitzgerald | 1 mg | EUR 526.8 |
|
Description: Goat anti Monkey IgG secondary antibody (Alk Phos) |
|||
Goat anti Monkey IgA (Alk Phos) |
|||
| 43C-CB1632 | Fitzgerald | 1 mg | EUR 517.2 |
|
Description: Goat anti Monkey IgA secondary antibody (Alk Phos) |
|||
Rabbit anti Mouse IgM (Alk Phos) |
|||
| 43C-CB5112 | Fitzgerald | 1 mg | EUR 570 |
|
Description: Rabbit anti Mouse IgM secondary antibody (Alk Phos) |
|||
Goat anti Mouse IgM (Alk Phos) |
|||
| 43C-CB5119 | Fitzgerald | 1 mg | EUR 522 |
|
Description: Goat anti Mouse IgM secondary antibody (Alk Phos) |
|||
Rabbit anti Mouse IgG1 (Alk Phos) |
|||
| 43C-CB5126 | Fitzgerald | 1 mg | EUR 536.4 |
|
Description: Rabbit anti Mouse IgG1 secondary antibody (Alk Phos) |
|||
Outcomes confirmed that top Cu publicity precipitated hepatocellular G0/G1 cell-cycle arrest (CCA) and lowered cell proportion within the G2/M part. G0/G1 CCA occurred with down-regulation (p < 0.05) of Ras, p-PI3K (Tyr458), p-Akt (Thr308), p-forkhead field O3 (FOXO3A) (Ser253), p-glycogen synthase kinase 3-β (GSK3-β) (Ser9), murine double minute 2 (MDM2) protein, and mRNA expression ranges, and up-regulation (p < 0.05) of PTEN, p-p53 (Ser15), p27, p21 protein, and mRNA expression ranges, which subsequently suppressed (p < 0.05) the protein and mRNA expression ranges of CDK2/Four and cyclin E/D. These outcomes point out that Cu publicity suppresses the Ras/PI3K/Akt signaling pathway to scale back the extent of CDK2/Four and cyclin E/D, that are important for the G1-S transition, and eventually causes hepatocytes G0/G1 CCA.
